s The failure of Gollmann-Bouw: Are their products what our market wants? | I2P: Information to Pharmacists - Archive
Publication Date 01/07/2014         Volume. 6 No. 6   
Information to Pharmacists


From the desk of the editor

Welcome to the July 2014 homepage edition of i2P (Information to Pharmacists) E-Magazine.
At the commencement of 2014 i2P focused on the need for the entire profession of pharmacy and its associated industry supports to undergo a renewal and regeneration.
We are now half-way through this year and it is quite apparent that pharmacy leaders do not yet have a cohesive and clear sense of direction.
Maybe the new initiative by Woolworths to deliver clinical service through young pharmacists and nurses may sharpen their focus.
If not, community pharmacy can look forward to losing a substantial and profitable market share of the clinical services market.
Who would you blame when that happens?
But I have to admit there is some effort, even though the results are but meagre.
In this edition of i2P we focus on the need for research about community pharmacy, the lack of activity from practicing pharmacists and when some research is delivered, a disconnect appears in its interpretation and implementation.

read more
open full screen

Recent Comments

Click here to read...

News Flash

Newsflash Updates for July 2014

Newsflash Updates

Regular weekly updates that supplement the regular monthly homepage edition of i2P. 
Access and click on the title links that are illustrated

Comments: 1

read more
open full screen

Feature Contribution

Woolworths Pharmacy - Getting One Stage Closer

Neil Johnston

It started with “tablet” computers deployed on shelves inside the retailer Coles, specifically to provide information to consumers relating to pain management and the sale of strong analgesics.
This development was reported in i2P under the title Coles Pharmacy Expansion and the Arid PGA Landscape”
In that article we reported that qualified information was a missing link that had come out of Coles market research as the reason to why it had not succeeded in dominating the pain market.
Of course, Woolworths was working on the same problem at the same time and had come up with a better solution - real people with good information.

Comments: 5

read more
open full screen

Intensive Exposition without crossing over with a supermarket

Fiona Sartoretto Verna AIAPP

Editor's Note: The understanding of a pharmacy's presentation through the research that goes into the design of fixtures and fittings that highlight displays, is a never-ending component of pharmacy marketing.
Over the past decade, Australian pharmacy shop presentations have fallen behind in standards of excellence.
It does not take rocket science - you just have to open your eyes.
Recently, our two major supermarkets, Woolworths and Coles, have entered into the field of drug and condition information provision - right into the heartland of Australian Pharmacy.

read more
open full screen

The sure way to drive business away

Gerald Quigley

I attended the Pregnancy, Baby and Children’s Expo in Brisbane recently.
What an eye and ear opening event that was!
Young Mums, mature Mums, partners of all ages, grandparents and friends……...many asking about health issues and seeking reassurances that they were doing the right thing.

Comments: 1

read more
open full screen

‘Marketing Based Medicine’ – how bad is it?

Baz Bardoe

It should be the scandal of the century.
It potentially affects the health of almost everyone.
Healthcare providers and consumers alike should be up in arms. But apart from coverage in a few credible news sources the problem of ‘Marketing Based Medicine,’ as psychiatrist Dr Peter Parry terms it, hasn’t as yet generated the kind of universal outrage one might expect.

read more
open full screen

Community Pharmacy Research - Are You Involved?

Mark Coleman

Government funding is always scarce and restricted.
If you are ever going to be a recipient of government funds you will need to fortify any application with evidence.
From a government perspective, this minimises risk.
I must admit that while I see evidence of research projects being managed by the PGA, I rarely see community pharmacists individually and actively engaged in the type of research that would further their own aims and objectives (and survival).

read more
open full screen

Organisational Amnesia and the Lack of a Curator Inhibits Cultural Progress

Neil Johnston

Most of us leave a tremendous impact on pharmacies we work for (as proprietors, managers, contractors or employees)—in ways we’re not even aware of.
But organisational memories are often all too short, and without a central way to record that impact and capture the knowledge and individual contributions, they become lost to time.
It is ironic that technology has provided us with phenomenal tools for communication and connection, but much of it has also sped up our work lives and made knowledge and memory at work much more ephemeral.

read more
open full screen

Academics on the payroll: the advertising you don't see

Staff Writer

This article was first published in The Conversation and was written by Wendy Lipworth, University of Sydney and Ian Kerridge, University of Sydney
In the endless drive to get people’s attention, advertising is going ‘native’, creeping in to places formerly reserved for editorial content. In this Native Advertising series we find out what it looks like, if readers can tell the difference, and more importantly, whether they care.
i2P has republished the article as it supports our own independent and ongoing investigations on how drug companies are involved in marketing-based medicine rather than evidence-based medicine.

read more
open full screen

I’ve been thinking about admitting wrong.

Mark Neuenschwander

Editor's Note: This is an early article by Mark Neuenschwander we have republished after the soul-searching surrounding a recent Australian dispensing error involving methotrexate.
Hmm. There’s more than one way you could take that, huh? Like Someday when I get around to it (I’m not sure) I may admit that I was wrong about something. Actually, I’ve been thinking about the concept of admitting wrong. So don’t get your hopes up. No juicy confessions this month except that I wish it were easier for me to admit when I have been wrong or made a mistake.
Brian Goldman, an ER physician from Toronto, is host of the award-winning White Coat, Black Art on CBC Radio and slated to deliver the keynote at The unSUMMIT for Bedside Barcoding in Anaheim this May. His TED lecture, entitled, “Doctors make mistakes. Can we talk about it?” had already been viewed by 386,072 others before I watched it last week.

read more
open full screen

Dispensing errors – a ripple effect of damage

Kay Dunkley - BPharm, Grad Dip Hosp Pharm, Grad Dip Health Admin, MPS, MSHPA

Most readers will be aware of recent publicity relating to dispensing errors and in particular to deaths caused by methotrexate being incorrectly packed in dose administration aids.
The Pharmacy Board of Australia (PBA), in its Communique of 13 June 2014, described a methotrexate packing error leading to the death of a patient and noted “extra vigilance is required to be exercised by pharmacists with these drugs”.
This same case was reported by A Current Affair (ACA) in its program on Friday 20 June

read more
open full screen

Take a vacation from your vocation

Harvey Mackay

Have you ever had one of those days when all you could think was, “Gosh, do I need a vacation.”
Of course you have – because all work and no play aren’t good for anyone.
A vacation doesn’t have to be two weeks on a tropical island, or even a long weekend at the beach. 
A vacation just means taking a break from your everyday activities. 
A change of pace. 
It doesn’t matter where.
Everyone needs a vacation to rejuvenate mentally and physically. 
But did you also know that you can help boost our economy by taking some days off? 
Call it your personal stimulus package.

read more
open full screen

Explainer: what is peer review?

Staff Writer

This article was first published in the Conversation. It caught our eye because "peer review" it is one of the standards for evidence-based medicines that has also been corrupted by global pharma.
The article is republished by i2P as part of its ongoing investigation into scientific fraud and was writtenby Andre Spicer, City University London and Thomas Roulet, University of Oxford
We’ve all heard the phrase “peer review” as giving credence to research and scholarly papers, but what does it actually mean?
How does it work?
Peer review is one of the gold standards of science. It’s a process where scientists (“peers”) evaluate the quality of other scientists' work. By doing this, they aim to ensure the work is rigorous, coherent, uses past research and adds to what we already knew.
Most scientific journals, conferences and grant applications have some sort of peer review system. In most cases it is “double blind” peer review. This means evaluators do not know the author(s), and the author(s) do not know the identity of the evaluators.
The intention behind this system is to ensure evaluation is not biased.
The more prestigious the journal, conference, or grant, the more demanding will be the review process, and the more likely the rejection. This prestige is why these papers tend to be more read and more cited.

read more
open full screen

Dentists from the dark side?

Loretta Marron OAM BSc

While dining out with an elderly friend, I noticed that he kept his false tooth plate in his shirt pocket. He had recently had seven amalgam-filled teeth removed, because he believed that their toxins were making him sick; but his new plate was uncomfortable. He had been treated by an 'holistic dentist'. Claiming to offer a "safe and healthier alternative" to conventional dentistry, are they committed to our overall health and wellbeing or are they promoting unjustified fear, unnecessarily extracting teeth and wasting our money?

read more
open full screen

Planning for Profit in 2015 – Your key to Business Success

Chris Foster

We are now entering a new financial year and it’s a great time to reflect on last year and highlight those things that went well and those that may have impacted negatively in the pursuit of your goals.
It's also a great to spend some time re-evaluating your personal and business short, medium and long term goals in the light of events over the last year.
The achievement of your goals will in many cases be dependent on setting and aspiring to specific financial targets. It's important that recognise that many of your personal goals will require you to generate sufficient business profits to fund those aspirations

read more
open full screen

ReWalk™ Personal Exoskeleton System Cleared by FDA for Home Use

Staff Writer

Exoskeleton leader ReWalk Robotics announced today that the U.S. Food and Drug Administration has cleared the company’s ReWalk Personal System for use at home and in the community.
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk.
ReWalk, the only exoskeleton with FDA clearance via clinical studies and extensive performance testing for personal use, is now available throughout the United States.

read more
open full screen

Attracting and Retaining Great People

Barry Urquhart

Welcome to the new financial year in Australia.
For many in business the past year has been described as a challenging period.
Adjectives are a key feature of the English language.  In the business lexicon their use can be, and often is evocative and stimulate creative images.  But they can also contribute to inexact, emotional perceptions.
Throughout the financial pages of newspapers and business magazines adjectives abound.
References to “hot” money draw attention and comment.  The recent wave of funds from Chinese investors, keen to remove their wealth from the jurisdiction and control of government regulations is creating a potential property bubble in Australia.

read more
open full screen

Updating Your Values - Extending Your Culture

Neil Johnston

Pharmacy culture is dormant.
Being comprised of values, unless each value is continually addressed, updated or deleted, entire organisations can stagnate (or entire professions such as the pharmacy profession).
Good values offer a strong sense of security, knowing that if you operate within the boundaries of your values, you will succeed in your endeavours.

read more
open full screen

Evidence-based medicine is broken. Why we need data and technology to fix it

Staff Writer

The following article is reprinted from The Conversation and forms up part of our library collection on evidence-based medicines.
At i2P we also believe that the current model of evidence is so fractured it will never be able to be repaired.
All that can happen is that health professionals should independently test and verify through their own investigations what evidence exists to prescribe a medicine of any potency.
Health professionals that have patients (such as pharmacists) are ideally placed to observe and record the efficacy for medicines.
All else should confine their criticisms to their evidence of the actual evidence published.
If there are holes in it then share that evidence with the rest of the world.
Otherwise, do not be in such a hurry to criticise professions that have good experience and judgement to make a good choice on behalf of their patients, simply because good evidence has not caught up with reality.

read more
open full screen

Laropiprant is the Bad One; Niacin is/was/will always be the Good One

Staff Writer

Orthomolecular Medicine News Service, July 25, 2014
Laropiprant is the Bad One; Niacin is/was/will always be the Good One
by W. Todd Penberthy, PhD

(OMNS July 25, 2014) Niacin has been used for over 60 years in tens of thousands of patients with tremendously favorable therapeutic benefit (Carlson 2005).
In the first-person NY Times best seller, "8 Weeks to a Cure for Cholesterol," the author describes his journey from being a walking heart attack time bomb to a becoming a healthy individual.
He hails high-dose niacin as the one treatment that did more to correct his poor lipid profile than any other (Kowalski 2001).

read more
open full screen

Culture Drive & Pharmacy Renewal

Neil Johnston

Deep within all of us we have a core set of values and beliefs that create the standards of behaviour that we align with when we set a particular direction in life.
Directions may change many times over a lifetime, but with life experiences and maturity values may increase in number or gain greater depth.
All of this is embraced under one word – “culture”.
When a business is born it will only develop if it has a sound culture, and the values that comprise that culture are initially inherent in the business founder.
A sound business culture equates to a successful business and that success is often expressed in the term “goodwill” which can be eventually translated to a dollar value.

read more
open full screen

ReWalk™ Personal Exoskeleton System Cleared by FDA for Home Use

Staff Writer

Exoskeleton leader ReWalk Robotics announced today that the U.S. Food and Drug Administration has cleared the company’s ReWalk Personal System for use at home and in the community.
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk.
ReWalk, the only exoskeleton with FDA clearance via clinical studies and extensive performance testing for personal use, is now available throughout the United States.

read more
open full screen

Pharmacy 2014 - Pharmacy Management Conference

Neil Johnston

The brave new world of health and wellness is not the enemy of Pharmacy, it is its champion.
Australian futurist, Morris Miselowski, one of the world's leading business visionaries, will present the Opening Keynote address on Pharmacy's Future in the new Health and Wellness Landscape at 2.00pm on Wednesday July 30.
Morris believes the key to better health care could already be in your pocket, with doctors soon set to prescribe iPhone apps, instead of pills.
Technology will revolutionise the health industry - a paradigm shift from healthcare to personal wellness.
Health and wellness applications on smartphones are already big news, and are dramatically changing the way we manage our personal health and everyday wellness.

read more
open full screen

Generation and Application of Community Pharmacy Research

Neil Johnston

Editor’s Note: We have had a number of articles in this issue relating to pharmacy research.
The PGA has conducted a number of research initiatives over the years, including one recently reported in Pharmacy News that resulted from an analysis of the QCPP Patient Questionnaire.
Pharmacy Guild president, George Tambassis, appears to have authored the article following, and there also appears to be a disconnect between the survey report and its target audience illustrated by one of the respondent comments published.
I have asked Mark Coleman to follow through, elaborate and comment:

read more
open full screen

The failure of Gollmann-Bouw: Are their products what our market wants?

Chris Wright

articles by this author...

Chris has spent many years in the pharmaceutical industry and is semi-retired.
He has an interest in supply chain procedures, and work flows within community pharmacies, and he provides consultancies around those activities.

Editor's Note - 15th November 2012:
When this article was first published in August 2010, Gollman-Bouw had entered into liquidation following a very turbulent period under the stewardship of Mark Bouw, managing director of the Australian enterprise.
Since that date the automated dispensing market has settled down and is now demonstrating steady and solid growth.
New people have entered into an agreement with German company Gollmann Systems and they have no relationship with any of the people associated with the former entity.
Many of the initial teething problems have been overcome and a better understanding of the Australian pharmacy market has emerged.
Gollmann Systems are globally competitive and contain innovations not seen in some of their competitors.
Any prospective purchaser should short-list this product when seeking a solution for their pharmacy.

open this article full screen

Was it folly for one of the giants of automaton, MTS Medication Technologies to enter the fray in Australia with a product such as the Easy-Med machine?
Whilst many pharmacists remain either suspicious or ambivalent about automation in general, the automation of DAA’s is attracting scrutiny because of rising volume.
Some 350,000 DAA packs are currently filled weekly, rising to up to one million in about 5 years.
The Easy-Med machine is a ripper, but for the price it doesn’t have enough bells & whistles to impress in the longer term, when DAA standards will rise.
I accept that it is a far better proposition to the much-maligned sachet machines, but that doesn’t mean much. After all, sachet machines get a bit of traction simply because of the absence of a better solution. At last count there were less than 20 sachet machines in Australia and about 40 in New Zealand. This imbalance is due in part to the Monty Pythonesque attitude of the NSW PGA who insist it must be “proved” that medicines supplied in an automated DAA are the original medicines dispensed.

Potential “show-stoppers” for the Easy-Med machine was always going to be its size and price when pharmacies account for the vast majority of this particular target market.

As for size, it is always going to be difficult to sell an automated solution into a pharmacy when the professional service area has to be redesigned. I’d venture the comment that it is far more palatable to spend money to accommodate a pack dispensing solution rather than a DAA solution, simply because of the dynamics of the business.

Did it escape Gollmann-Bouw that the size of the Easy-Med machine meant an additional investment was likely to be mandatory in most pharmacies?

It’s a bit like every student should have a computer………just pity the installation costs were ignored, thus doubling the cost of the plan.

However, being an almost pathological devotee of automation in pharmacy I’d like to see the Easy-Med machine represented here. The question is who will step into the breach?

Certainly it might be said that the Americans and Germans view Australia as a bit of a technological backwater and their respective forays into our backyard have had an element of an Irish social club playing darts after an exhaustive tasting of Guinness about it in the past.

That said, to be successful MTS will need to address the manner in which their product is represented here.

To source the price of the Easy-Med machine was a challenge.

I called Gollmann-Bouw to ask this very question and while waiting for an obviously very busy sales department to answer the phone I conjured up visions of a Telsta call-centre type environment busily taking orders.

Anyway, for those amongst you who enjoy “Yes, Minister”.

Sales Person (SP). “Hello, can I help you”?

Chris Wright (CW) “Yes, thank you. I’m inquiring as to the price of the Easy-Med


SP. “How many scripts do you do?”

CW. “Is script volume relevant to the price of the machine?”

SP. “No”.

CW. “In that case I just need to know the price.”

SP. “But I need to know how many scripts you do”.

CW. “I don’t do any”.

SP. “Are you a pharmacist?”

CW. “No, I’m not”.

SP. “So why do you want to know the price?”

CW. “I act for a group interested in automation”.

SP. “Who are they!” (Sounding very much like Margaret Thatcher.)

CW. “A group who won’t be buying the machine until they find out the price.”

And it went on…..such a strange marketing tactic.

However, the point is; Gollmann-Bouw (like many automated providers) rightly or wrongly was clearly fixated on advising a “transaction” price as a sales strategy.

In my view, wrong, wrong, wrong…….

Also, did it escape Gollmann that despite the fact the G-Series is a brilliant machine it denies the pharmacist valuable time.

As fellow i2p writer Garry Boyd commented in i2p in May 2009.

A video of the very impressive Gollmann G-Series machine shows the pharmacist leaving the patient to walk to the delivery point to retrieve the patient’s medicine. This takes about 8 seconds, yet the Gollmann G-Series exhorts a retrieval time of 8 to 15 seconds.

At 500 prescriptions a day, the pharmacist is spending an hour a day walking to the retrieval point and back to the patient!

Isn’t this ridiculous waste of time exactly what pharmacists are trying to avoid?

Brilliant machines do not necessarily deliver brilliant solutions.

Whilst this is not uncommon it is the myriad of tiny little issues that end up blowing such assumptions out of the water.

It may come as a surprise to some, but pharmacists are actually pretty cluey people.

I don’t know of any that aren’t capable of establishing a business case to introduce an automated solution to their business………..providing they know the price.

Chris Wright.
August 2010.



Return to home

Submitted by D Jackman on Sat, 05/01/2013 - 07:38.

Pertaining to the commments about the 8 seconds of time away from the customer...
I worked for Gollmann and now for Rowa as International Commissioning Engineer thus making me the only person truly qualified to comment on the two complete automation solutions available to the Australian market. my question to you CW is did you ever ask if it it possible to deliver the packages direct to the point of dispense.

Submitted by Peter P Rod on Wed, 04/08/2010 - 13:04.

I would have expected the Guild to have examined all these issues before giving the Gollmann-Bouw product its seal of approval. It seems to me that had the Guild been more circumspect and less focused on its own commercial self interest it may well have decided that no matter how brilliant the machine it would not find market acceptance in Australia. Have I missed something Charles?

Submitted by Rollo on Wed, 04/08/2010 - 06:47.

You say "Some 350,000 DAA packs are currently filled weekly, rising to up to one million in about 5 years."
Please advise source of this figure?

Submitted by Chris Wright on Fri, 06/08/2010 - 16:19.

The current 350,000 is an assessment based on a range of disparate information, some of which is from industry bodies.
In my experience I conclude that approximately 1,000 pharmacies provide somewhere between 200 and 400 DAA's per week to the RCF market, of which there is in excess of 160,000 beds.
Adding to this is the indigenous population (supplied under s100 conditions), shipping, pastoral, mining and those confined at her Majesty's pleasure. And not forgetting of course patients living in their own homes with the aid of "assisted care".
The assisted care market will no doubt rise dramatically due to the expected lack of RCF beds in the future and the fact baby-boomers are approaching an age consistent with medical dependency.
Therefore, the figure of a million per week seems reasonably accurate, albeit having been arrived at empirically.
Good question, Rollo.

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

More information about formatting options

health news headlines provided courtesy of Medical News Today.

Click here to

If any difficulty is found in subscribing, please use the "Contact Us" panel found in the navigation bar with the message "subscribe" and your email address.

Subscribe to our mailing list

Email Format


  • Copyright (C) 2000-2020 Computachem Services, All Rights Reserved.

Website by Ablecode